HEMATOLOGY

Progression-free survival was extended by 3.6 months with higher-dose, once-weekly carfilzomib (Kyprolis) compared with a lower-dose, twice-weekly regimen in patients with relapsed/refractory multiple myeloma, according to according to phase III results from the ARROW trial.

Understanding genetic abnormalities is key to better improving outcomes in multiple myeloma, particularly for high-risk patients, Shaji K. Kumar, MD, said in his talk at the 35th annual CFS.

Vancheswaran Gopalakrishnan, MPH, a post-doctorate fellow in Dr. Jennifer Wargo's laboratory at The University of Texas MD Anderson Cancer Center, discusses a study that explored the diversity and composition of the gut microbiome in melanoma patients and its influence on response to anti-PD-1 therapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting. Dr. Gopalakrishnan completed this study under the mentorship of Dr. Wargo, who was the principal investigator. 

Owen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the agents approved by the FDA for the treatment of mantle cell lymphoma (MCL), including acalabrutinib (Calquence) and bortezomib (Velcade).

According to results from the phase III phase III LyMa trial published in the <em>New England Journal of Medicine, </em>survival was improved for patients with mantle cell lymphoma with maintenance&nbsp;rituximab (Rituxan) following autologous stem-cell transplantation (ASCT).

Andre Goy, MD,&nbsp;discusses the excitement surrounding novel therapies on the horizon in mantle cell lymphoma, as well as how the treatment paradigm will shift in the next 5 to 10 years.

Over the past few years, remarkable advances have been achieved in the field of CLL by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival. These developments have been achieved by a better understanding of the underlying biology and the disease process.

Checkpoint-based immune therapies have revolutionized the therapy of solid tumors by achieving breakthrough improvements in melanoma, lung cancer, renal cancer, bladder cancers, and head and neck tumors, among others.

Ruben Mesa, MD, director, UT Health San Antonio Cancer Center, discusses NCCN guideline updates in polycythemia vera and essential thrombocythemia.

Vemurafenib (Zelboraf) has been granted approval by the FDA&nbsp;as a treatment for patients with <em>BRAF</em> V600-mutated Erdheim-Chester disease (ECD). This is the first approved therapy for this rare blood disorder.

Brentuximab vedotin&nbsp;(Adcetris) has been submitted for FDA approval in combination with Adriamycin, vinblastine, dacarbazine for the frontline treatment of patients with&nbsp;advanced classical Hodgkin lymphoma.&nbsp;Seattle Genetics,&nbsp;the company developing brentuximab vedotin, recently announced the submission of a&nbsp;supplemental new drug application for the&nbsp;CD30-targeted antibody-drug conjugate.

The B-cell maturation antigen antibody-drug conjugate&nbsp;GSK2857916 has been granted a breakthrough therapy designation by the FDA for the treatment of patients with relapsed/refractory multiple myeloma,&nbsp;GlaxoSmithKline has announced.

Sandy Wong, MD, assistant professor, Division of Hematology/Oncology, UCSF School of Medicine, discusses the progress that has been made with monocloncal antibodies for the treatment of plasma cell neoplasms.

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease (MRD) in patients with acute myeloid leukemia (AML).

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the management of newly diagnosed patients with multiple myeloma.

The treatment approach for patients with relapsed/refractory multiple myeloma should be tailored based on biology of the disease, frailty of the patient, and comorbidities, said Natalie S. Callander, MD, in a presentation at the NCCN 12th Annual Congress: Hematologic Malignancies in San Francisco, California.

According to phase II results from the DSMM XI trial published in the <em>British Journal of Haematology</em>, induction therapy with bortezomib (Velcade), cyclophosphamide, and dexamethasone demonstrated an overall response rate of 85.4%&nbsp;in treatment-na&iuml;ve patients with multiple myeloma.

In patients with newly diagnosed multiple myeloma, maintenance therapy with lenalidomide (Revlimid)&nbsp;induced a survival benefit following autologous stem-cell transplantation, according to results from a meta-analysis published in the <em>Journal of Clinical Oncology</em>.

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses sequencing agents in chronic lymphocytic leukemia (CLL).

Although preclinical data are promising, there are many clinical challenges in developing CAR T-cell therapy in acute myeloid leukemia.

The CD19-directed CAR T-cell therapy&nbsp;axicabtagene ciloleucel (axi-cel; Yescarta) has been approved by the FDA for the treatment of adults with relapsed or refractory non-Hodgkin lymphoma (NHL), based on complete remission (CR) rate results from the phase II ZUMA-1 trial.

Robert Z. Orlowski, MD, PhD, recently discussed 2 cases of patients with multiple myeloma, and the treatment considerations and decisions he would make when treating these patients. Orlowski, chairman, ad interim, director of myeloma, and professor of medicine, The University of Texas MD Anderson Cancer Center, discussed these cases during a&nbsp;<em>Targeted Oncology</em>&nbsp;live case-based peer perspectives dinner.

Gilteritinib has been granted Fast Track designation by the FDA for adult patients with&nbsp;FLT3 mutation-positive relapsed/refractory acute myeloid leukemia, according to Tokyo-based Astellas Pharma.

According to a multivariate analysis of the Nordic MCL2 and MCL3 trials, the presence of <em>TP53</em> mutations predicts overall survival in younger patients with mantle cell lymphoma.

Srdan Verstovsek, MD, PhD, recently discussed treatment considerations and decisions in the cases of 2 patients with myeloproliferative neoplasms.&nbsp;Verstovsek,&nbsp;professor of medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discussed the case scenarios during a&nbsp;<em>Targeted Oncology</em>&nbsp;live case-based peer perspectives dinner.